This is a news story, published by CNBC, that relates primarily to PrEP news.
For more PrEP news, you can click here:
more PrEP newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Gilead. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest preventative HIV medicine news, HIV medicines news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
lenacapavir trial results ThursdayCNBC
•86% Informative
None of the roughly 2,000 women in the trial who received the shot, lenacapavir, contracted HIV.
The results bring Gilead one step closer to introducing a new form of pre-exposure prophylaxis, or PrEP , and broadening its HIV business.
The company needs to replicate the results in another Phase 3 trial before seeking FDA approval.
VR Score
90
Informative language
92
Neutral language
55
Article tone
semi-formal
Language
English
Language complexity
43
Offensive language
likely offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
7
Affiliate links
no affiliate links